Videos

Gregory Piazza, MD, MS, discusses the results of ROXI-CATH, which illustrated amrecibart’s and cenvacibart’s efficacy in reducing thrombosis events without increasing bleeding.

Raj Vuppalanchi, MD, explains how liver stiffness is becoming a prognostic tool in PBC and PSC, and why context matters when interpreting the number.

IL-33-targeted therapy may reach most patients with COPD regardless of eosinophil count, but questions remain about how drugs act on its 2 forms.

Pavel Strnad, MD, discusses pooled phase 2 data showing fazirsiran cut liver Z-AAT burden by about 90% in AATD liver disease and why screening matters now.

Timucin Taner, MD, PhD, explains how to reduce long-term immunosuppression after liver transplant, who to start with, and why biomarkers remain the gap.

Zobair Younossi, MD, MPH, discusses MAESTRO-NAFLD-1 data linking resmetirom to improved worry and health distress scores in compensated MASH cirrhosis.

Quantitative HBsAg testing now determines which patients on antiviral therapy may qualify for bepirovirsen, a finite add-on treatment for chronic hepatitis B.

Marlyn Mayo, MD, discusses long-term seladelpar data linking IL-31 reductions to PBC pruritus improvement and why the cytokine is not ready to guide treatment.

IL-33 has 2 forms in COPD: oxidized IL-33 drives mucus dysfunction, while reduced IL-33 recruits inflammatory cells, with implications for mucus plugging.

Sebastian outlines a tiered carotid imaging strategy and the CTA findings pointing to dissection, vasculitis, or intraluminal thrombus.

In ZIPS-2, 20 mg daily zinc reduced all-cause infection rates by 38% vs placebo in Ugandan children with sickle cell anemia aged <5 years.

Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.

Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.

Sebastian outlines why carotid webs, symptomatic non-stenotic carotid disease, and dissection can be missed when stroke workups focus on luminal narrowing.

Marat Fudim, MD, discusses his analysis of a US cohort from the POSEIDON study, which found a potential association between CVI and HF severity.

Bradley Dixon, MD, discusses VALIANT+VALE data showing sustained proteinuria reduction and stable eGFR through 76 weeks in adolescents with C3G or IC-MPGN.

Bradley Dixon, MD, discusses VALIANT+VALE data showing sustained proteinuria reduction and stable eGFR through 76 weeks in adolescents with C3G or IC-MPGN.

Tobias Uhe, MD, discusses the results of the Find-AF 2 Watch trial, examining 2 different smart watches as AF monitors in patients with a recent ischemic stroke.

Shakar Kutal, a doctoral researcher at Helsinki University, discusses his study evaluating the role of dietary factors in early-onset CIS among young adults.

Katie Harris, PhD, discusses her MRI substudy of the TRIDENT trial, evaluating the role of T2 lesions, white matter hypersensitivity, and brain volume on dementia.

Raed Joundi, MD, discusses the implications of his substudy of OCEANIC-STROKE and how it could change secondary prevention in ischemic stroke care.

October 2026 hepatology news includes FDA approval of bepirovirsen for hepatitis B, new ACLF criteria, ACG cirrhosis guidance, and MASH trial data.

Raed Joundi, MD, discusses his substudy of the OCEANIC-STROKE trial, demonstrating the safety of Bayer’s investigational FXIa inhibitor across the spectrum of infarct patterns.

Correll discusses functional outcomes from SOLARIS and how to monitor and mitigate weight gain with once-monthly subcutaneous olanzapine.

Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.

Moshe Prero, MD, says bronchopulmonary dysplasia remains relevant into adulthood and details home safety priorities for children with tracheostomies.

John Cleland, MD, PhD, discusses the results of the HF-TRACK study and the potential for the Heartfelt device to improve HF outcomes among monitored patients.

Nathan explains why a TETON-2 post hoc analysis of recurrent events, 126 vs 161 with placebo, supports continuing inhaled treprostinil after progression.